Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer
The 5-year survival rate in the early and late stages of ovarian cancer differs by 63%. In addition, a liquid biopsy is necessary because there are no symptoms in the early stage and tissue collection is difficult without using invasive methods. Therefore, there is a need for biomarkers to achieve t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/11/3447 |
| _version_ | 1797547370481713152 |
|---|---|
| author | Hee-Sung Ahn Jeonghun Yeom Jiyoung Yu Young-Il Kwon Jae-Hoon Kim Kyunggon Kim |
| author_facet | Hee-Sung Ahn Jeonghun Yeom Jiyoung Yu Young-Il Kwon Jae-Hoon Kim Kyunggon Kim |
| author_sort | Hee-Sung Ahn |
| collection | DOAJ |
| description | The 5-year survival rate in the early and late stages of ovarian cancer differs by 63%. In addition, a liquid biopsy is necessary because there are no symptoms in the early stage and tissue collection is difficult without using invasive methods. Therefore, there is a need for biomarkers to achieve this goal. In this study, we found blood-based metabolite or protein biomarker candidates for the diagnosis of ovarian cancer in the 20 clinical samples (10 ovarian cancer patients and 10 healthy control subjects). Plasma metabolites and proteins were measured and quantified using mass spectrometry in ovarian cancer patients and control groups. We identified the differential abundant biomolecules (34 metabolites and 197 proteins) and statistically integrated molecules of different dimensions to better understand ovarian cancer signal transduction and to identify novel biological mechanisms. In addition, the biomarker reliability was verified through comparison with existing research results. Integrated analysis of metabolome and proteome identified emerging properties difficult to grasp with the single omics approach, more reliably interpreted the cancer signaling pathway, and explored new drug targets. Especially, through this analysis, proteins (PPCS, PMP2, and TUBB) and metabolites (L-carnitine and PC-O (30:0)) related to the carnitine system involved in cancer plasticity were identified. |
| first_indexed | 2024-03-10T14:43:16Z |
| format | Article |
| id | doaj.art-c6ae8542c7524816aaf79b30a59d7a87 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T14:43:16Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c6ae8542c7524816aaf79b30a59d7a872023-11-20T21:36:25ZengMDPI AGCancers2072-66942020-11-011211344710.3390/cancers12113447Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian CancerHee-Sung Ahn0Jeonghun Yeom1Jiyoung Yu2Young-Il Kwon3Jae-Hoon Kim4Kyunggon Kim5Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaConvergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaThe K-Clinic Royal HIFU Center, Seoul 06232, KoreaDepartment of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06237, KoreaAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaThe 5-year survival rate in the early and late stages of ovarian cancer differs by 63%. In addition, a liquid biopsy is necessary because there are no symptoms in the early stage and tissue collection is difficult without using invasive methods. Therefore, there is a need for biomarkers to achieve this goal. In this study, we found blood-based metabolite or protein biomarker candidates for the diagnosis of ovarian cancer in the 20 clinical samples (10 ovarian cancer patients and 10 healthy control subjects). Plasma metabolites and proteins were measured and quantified using mass spectrometry in ovarian cancer patients and control groups. We identified the differential abundant biomolecules (34 metabolites and 197 proteins) and statistically integrated molecules of different dimensions to better understand ovarian cancer signal transduction and to identify novel biological mechanisms. In addition, the biomarker reliability was verified through comparison with existing research results. Integrated analysis of metabolome and proteome identified emerging properties difficult to grasp with the single omics approach, more reliably interpreted the cancer signaling pathway, and explored new drug targets. Especially, through this analysis, proteins (PPCS, PMP2, and TUBB) and metabolites (L-carnitine and PC-O (30:0)) related to the carnitine system involved in cancer plasticity were identified.https://www.mdpi.com/2072-6694/12/11/3447liquid biopsyovarian cancermetabolomeproteomeLC–MS/MSFIA–MS/MS |
| spellingShingle | Hee-Sung Ahn Jeonghun Yeom Jiyoung Yu Young-Il Kwon Jae-Hoon Kim Kyunggon Kim Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer Cancers liquid biopsy ovarian cancer metabolome proteome LC–MS/MS FIA–MS/MS |
| title | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer |
| title_full | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer |
| title_fullStr | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer |
| title_full_unstemmed | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer |
| title_short | Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer |
| title_sort | convergence of plasma metabolomics and proteomics analysis to discover signatures of high grade serous ovarian cancer |
| topic | liquid biopsy ovarian cancer metabolome proteome LC–MS/MS FIA–MS/MS |
| url | https://www.mdpi.com/2072-6694/12/11/3447 |
| work_keys_str_mv | AT heesungahn convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer AT jeonghunyeom convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer AT jiyoungyu convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer AT youngilkwon convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer AT jaehoonkim convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer AT kyunggonkim convergenceofplasmametabolomicsandproteomicsanalysistodiscoversignaturesofhighgradeserousovariancancer |